q-griffithsin
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 11, 2021 (NCT05122260)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CandidaINHIBITOR
Candida inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05437029 | Phase 1 | Jun 15, 2022 | Department of Defense, University of Louisville |
| NCT05180500 | Phase 1 | Mar 15, 2022 | National Cancer Institute (NCI), University of Pittsburgh |
| NCT05122260 | Phase 1 | Nov 11, 2021 | Department of Defense, University of Louisville |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Defense | Government | 2 | 0 | 1 | 2021 |
| University of Louisville | Academic/Hospital | 2 | 2 | 1 | 2021 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2022 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2022 |
4 organizations
Page 1 / 1